Autologous transplantation and maintenance therapy in multiple myeloma

A. Palumbo, F. Cavallo, F. Gay, F. Di Raimondo, D. B. Yehuda, M. T. Petrucci, S. Pezzatti, T. Caravita, C. Cerrato, E. Ribakovsky, M. Genuardi, A. Cafro, M. Marcatti, L. Catalano, M. Offidani, A. M. Carella, E. Zamagni, F. Patriarca, P. Musto, A. EvangelistaG. Ciccone, P. Omedé, C. Crippa, P. Corradini, A. Nagler, M. Boccadoro, M. Cavo

Research output: Contribution to journalArticlepeer-review


Background: This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantation with melphalan-prednisone-lenalidomide (MPR) and compared lenalidomide maintenance therapy with no maintenance therapy in patients with newly diagnosed multiple myeloma. Methods: We randomly assigned 273 patients 65 years of age or younger to high-dose melphalan plus stem-cell transplantation or MPR consolidation therapy after induction, and 251 patients to lenalidomide maintenance therapy or no maintenance therapy. The primary end point was progression-free survival. Results: The median follow-up period was 51.2 months. Both progression-free and overall survival were significantly longer with high-dose melphalan plus stem-cell transplantation than with MPR (median progression-free survival, 43.0 months vs. 22.4 months; hazard ratio for progression or death, 0.44; 95% confidence interval [CI], 0.32 to 0.61; P

Original languageEnglish
Pages (from-to)895-905
Number of pages11
JournalNew England Journal of Medicine
Issue number10
Publication statusPublished - Sep 4 2014

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Autologous transplantation and maintenance therapy in multiple myeloma'. Together they form a unique fingerprint.

Cite this